about
Rabies Control and Treatment: From Prophylaxis to Strategies with Curative PotentialBiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells.VHH-Based Bispecific Antibodies Targeting Cytokine ProductionSingle domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells.CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy.A bi-specific inhibitor targeting IL-17A and MMP-9 reduces invasion and motility in MDA-MB-231 cells.Bispecific antibodies in cancer immunotherapy
P2860
Q28076429-3BE83F76-745D-45C5-9FD2-5AD2BF497961Q41302727-74E13BED-E4CE-4AD8-9D43-81A85CD725BBQ41619629-4981DE3E-9397-4665-A1EF-AC95F5420BACQ48193189-109FB389-BF8A-42D9-9AAF-ACFC312E325AQ52731744-352763E8-BF0D-4764-9FFF-35159E9F14CFQ55504448-F7A00510-1C49-4B37-BDBF-945C672A3B3FQ56893015-9DB7907C-4D11-4BD7-8AAF-2819734D9428
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Bispecific antibodies in cancer immunotherapy.
@en
Bispecific antibodies in cancer immunotherapy.
@nl
type
label
Bispecific antibodies in cancer immunotherapy.
@en
Bispecific antibodies in cancer immunotherapy.
@nl
prefLabel
Bispecific antibodies in cancer immunotherapy.
@en
Bispecific antibodies in cancer immunotherapy.
@nl
P2093
P2860
P1476
Bispecific antibodies in cancer immunotherapy.
@en
P2093
P2860
P304
P356
10.1080/21645515.2016.1187802
P577
2016-06-01T00:00:00Z